Ramiro Guerrero Acquires 11,899 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 11,899 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was bought at an average price of $1.37 per share, with a total value of $16,301.63. Following the completion of the purchase, the director owned 600,117 shares of the company’s stock, valued at $822,160.29. This trade represents a 2.02% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

MAIA Biotechnology Price Performance

Shares of MAIA opened at $1.41 on Wednesday. The stock has a fifty day moving average price of $1.37 and a 200 day moving average price of $1.45. The company has a market cap of $85.77 million, a P/E ratio of -2.27 and a beta of 0.24. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Solas Capital Management LLC acquired a new stake in MAIA Biotechnology in the second quarter worth about $4,364,000. Centric Wealth Management bought a new stake in shares of MAIA Biotechnology during the 2nd quarter worth about $1,107,000. Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology during the 2nd quarter worth about $741,000. BlackRock Inc. acquired a new stake in shares of MAIA Biotechnology in the 2nd quarter worth approximately $580,000. Finally, Corsair Capital Management L.P. bought a new position in shares of MAIA Biotechnology in the first quarter valued at approximately $140,000. 5.65% of the stock is owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.